Article
Tumor-immune microenvironment and NRF2 associate with clinical efficacy of PD-1 blockade combined with chemotherapy in lung squamous cell carcinoma.
Cell reports. Medicine - 19 Dec 2023
Duan Jianchun, Zhang Yun, Chen Ran, Liang Liang, Huo Yi, Lu Shun, Zhao Jun, Hu Chunhong, Sun Yuping, Yang Kunyu, Chen Mingwei, Yu Yan, Ying Jianming, Huang Ruiqi, Ma Xiaopeng, Leaw Shiangjiin, Bai Fan, Shen Zhirong, Cai Shangli, Gao Daming, Wang Jie, Wang Zhijie
Abstract excerpt
The RATIONALE-307 study (ClinicalTrials.gov: NCT03594747) demonstrates prolonged progression-free survival (PFS) with first-line tislelizumab plus chemotherapy versus chemotherapy in advanced lung squamous cell carcinoma (LUSC; N = 360). Here we describe an immune-related gene expression signature (GES), composed of genes involved in both innate and adaptive immunity, that appears to differentiate tislelizumab...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.